Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

CAPS Rating: 2 out of 5

The Company develops therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer's disease.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 11/14/2012 9:14:01 PM : Underperform Start Price: $2.07 PRAN Score: -6.68

downward spiral

Featured Broker Partners


Advertisement